Phase I Study of Adenoviral Delivery of the HSV-tk Gene and Ganciclovir Administration in Patients with Recurrent Malignant Brain Tumors

Molecular Therapy

Volumn 1, Issue 2, 2000, Pages 195-203

  Trask, Todd W ^a   Trask, Rebecca P ^a   Aguilar Cordova, Estuardo ^a,b   Shine, H David ^a   Wyde, Philip R ^a   Goodman, J Clay ^a   Hamilton, Winifred J ^a   Rojas Martinez, Augusto ^a,b   Chen, Shu Hsia ^c   Woo, Savio L C ^c   Grossman, Robert G ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus; Astrocytoma; Ganciclovir; Gene therapy; Glioblastoma; HSV tk; Stereotaxic technique

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; THYMIDINE KINASE;

ADENOVIRUS; ADULT; AGED; ARTICLE; ASTROCYTOMA; AVIAN SARCOMA VIRUS; BRAIN TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; ENZYMOLOGY; FEMALE; GENE THERAPY; GENE VECTOR; GENETICS; GLIOBLASTOMA; GLIOSARCOMA; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL; PROMOTER REGION; RADIOGRAPHY; TIME; TREATMENT OUTCOME;

ADENOVIRIDAE; ADULT; AGED; ANTIVIRAL AGENTS; ASTROCYTOMA; AVIAN SARCOMA VIRUSES; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; GLIOBLASTOMA; GLIOSARCOMA; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS (GENETICS); SIMPLEXVIRUS; THYMIDINE KINASE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034136802     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0030     Document Type: Article

References (53)

1. American Cancer Society, 1999, 1999 New Facts and Figures: Estimated New Cancer Cases and Deaths, http://www.cancer.org/statistics/cff99/data/data_newCaseSex.html .
2. Shrieve D. C., Alexander E. III, Black P. M., Wen P. Y., Fine H. A., Kooy H. M., Loeffler J. S. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: Prognostic factors and long-term outcome. J. Neurosurg. 90:1999;72-77.
3. Barker F. G. II, Chang S. M., Gutin P. H., Malec M. K., McDermott M. W., Prados M. D., Wilson C. B. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery. 42:1998;709-723.
4. Durmaz R., Erken S., Arslantas A., Atasoy M. A., Bal C., Tel E. Management of glioblastoma multiforme: With special reference to recurrence. Clin. Neurol. Neurosurg. 99:1997;117-123.
5. Black P. Management of malignant glioma: Role of surgery in relation to multimodality therapy. J. Neurovirol. 4:1998;227-236.
6. Mizuno M., Yoshida J., Colosi P., Kurtzman G. Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration. Jpn. J. Cancer Res. 89:1998;76-80.
7. Perez-Cruet M. J., Trask T. W., Chen S. H., Goodman J. C., Woo S. L., Grossman R. G., Shine H. D. Adenovirus-mediated gene therapy of experimental gliomas. J. Neurosci. Res. 39:1994;506-511.
8. Colak A., Goodman J. C., Chen S. H., Woo S. L., Grossman R. G., Shine H. D. Adenovirus-mediated gene therapy in an experimental model of breast cancer metastatic to the brain. Hum. Gene Ther. 6:1995;1317-1322.
9. Colak A., Goodman J. C., Chen S. H., Woo S. L., Grossman R. G., Shine H. D. Adenovirus-mediated gene therapy for experimental spinal cord tumors: Tumoricidal efficacy and functional outcome. Brain Res. 691:1995;76-82.
10. Chen S. H., Shine H. D., Goodman J. C., Grossman R. G., Woo S. L. Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA. 91:1994;3054-3057.
11. Lanuti M., Gao G. P., Force S. D., Chang M. Y., El Kouri C., Amin K. M., Hughes J. V., Wilson J. M., Kaiser L. R., Albelda S. M. Evaluation of an E1-E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Hum. Gene Ther. 10:1999;463-475.
12. Viola J. J., Ram Z., Walbridge S., Oshiro E. M., Trapnell B., Tao-Cheng J. H., Oldfield E. H. Adenovirally mediated gene transfer into experimental solid brain tumors and leptomeningeal cancer cells. J. Neurosurg. 82:1995;70-76.
13. Elshami A. A., Saavedra A., Zhang H., Kucharczuk J. C., Spray D. C., Fishman G. I., Amin K. M., Kaiser L. R., Albelda S. M. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 3:1996;85-92.
14. Carystinos G. D., Katabi M. M., Laird D. W., Galipeau J., Chan H., Alaoui-Jamali M. A., Batist G. Cyclic-AMP induction of gap junctional intercellular communication increases bystander effect in suicide gene therapy. Clin. Cancer Res. 5:1999;61-68.
15. Estin D., Li M., Spray D., Wu J. K. Connexins are expressed in primary brain tumors and enhance the bystander effect in gene therapy. Neurosurgery. 44:1999;361-369.
16. Hamel W., Magnelli L., Chiarugi V. P., Israel M. A. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res. 56:1996;2697-2702.
17. Ramesh R., Munshi A., Marrogi A. J., Freeman S. M. Enhancement of tumor killing using a combination of tumor immunization and HSV-tk suicide gene therapy. Int. J. Cancer. 80:1999;380-386.
18. Ramesh R., Munshi A., Abboud C. N., Marrogi A. J., Freeman S. M. Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene. Cancer Gene Ther. 3:1996;373-384.
19. Vile R. G., Nelson J. A., Castleden S., Chong H., Hart I. R. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54:1994;6228-6234.
20. Shine H. D., Wyde P. R., Aguilar-Cordova E., Chen S. H., Woo S. L., Grossman R. G., Goodman J. C. Neurotoxicity of intracerebral injection of a replication-defective adenoviral vector in a semipermissive species (cotton rat). Gene Ther. 4:1997;275-279.
21. Smith J. G., Raper S. E., Wheeldon E. B., Hackney D., Judy K., Wilson J. M., Eck S. L. Intracranial administration of adenovirus expressing HSV-TK in combination with ganciclovir produces a dose-dependent, self-limiting inflammatory response. Hum. Gene Ther. 8:1997;943-954.
22. Goodman J. C., Trask T. W., Chen S. H., Woo S. L., Grossman R. G., Carey K. D., Hubbard G. B., Carrier D. A., Rajagopalan S., Aguilar-Cordova E., Shine H. D. Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: Pathologic, radiologic, and molecular studies. Hum. Gene Ther. 7:1996;1241-1250.
23. Driesse M. J., Vincent A. J., Sillevis Smitt P. A., Kros J. M., Hoogerbrugge P. M., Avezaat C. J., Valerio D., Bout A. Intracerebral injection of adenovirus harboring the HSVtk gene combined with ganciclovir administration: Toxicity study in nonhuman primates. Gene Ther. 5:1998;1122-1129.
24. Graham F., Prevec L. Manipulation of adenovirus vectors. Murray E. J. Gene Transfer and Expression Protocols. 1991;109-127 Humana Press, Clifton.
25. Nyberg-Hoffman C., Shabram P., Li W., Giroux D., Aguilar-Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat. Med. 3:1997;808-811.
26. National Cancer Institute Cancer Therapy Evaluation Program, 1999, Common Toxicity Criteria (CTC), Version 2.0, April 30, 1999, http://ctep.info.nih.gov/CTC3/ctc.htm .
27. Singhal S., Kaiser L. R. Cancer chemotherapy using suicide genes. Surg. Oncol. Clin. N. Am. 7:1998;505-536.
28. Li H., Alonso-Vanegas M., Colicos M. A., Jung S. S., Lochmuller H., Sadikot A. F., Snipes G. J., Seth P., Karpati G., Nalbantoglu J. Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clin. Cancer Res. 5:1999;637-642.
29. Gomez-Manzano C., Fueyo J., Alameda F., Kyritsis A. P., Yung W. K. Gene therapy for gliomas: p53 and E2F-1 proteins and the target of apoptosis. Int. J. Mol. Med. 3:1999;81-85.
30. Visse E., Siesjo P., Widegren B., Sjogren H. O. Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-gamma, interleukin-7, or B7-1-transfected tumor cells. Cancer Gene Ther. 6:1999;37-44.
31. Liau L. M., Fakhrai H., Black K. L. Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene. Neurol. Res. 20:1998;742-747.
32. Ambar B. B., Frei K., Malipiero U., Morelli A. E., Castro M. G., Lowenstein P. R., Fontana A. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. Hum. Gene Ther. 10:1999;1641-1648.
33. Lang F. F., Yung W. K., Raju U., Libunao F., Terry N. H., Tofilon P. J. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene. J. Neurosurg. 89:1998;125-132.
34. Badie B., Kramar M. H., Lau R., Boothman D. A., Economou J. S., Black K. L. Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors. J. Neurooncol. 37:1998;217-222.
35. Ram Z., Walbridge S., Shawker T., Culver K. W., Blaese R. M., Oldfield E. H. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J. Neurosurg. 81:1994;256-260.
36. Galipeau J., Li H., Paquin A., Sicilia F., Karpati G., Nalbantoglu J. Vesicular stomatitis virus G pseudotyped retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer. Cancer Res. 59:1999;2384-2394.
37. Benedetti S., Bruzzone M. G., Pollo B., DiMeco F., Magrassi L., Pirola B., Cirenei N., Colombo M. P., Finocchiaro G. Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene. Cancer Res. 59:1999;645-652.
38. Tamura M., Ikenaka K., Tamura K., Yoshimatsu T., Miyao Y., Kishima H., Mabuchi E., Shimizu K. Transduction of glioma cells using a high-titer retroviral vector system and their subsequent migration in brain tumors. Gene Ther. 5:1998;1698-1704.
39. Kondo S., Tanaka Y., Kondo Y., Ishizaka Y., Hitomi M., Haqqi T., Liu J., Barnett G. H., Alnemri E. S., Barna B. P. Retroviral transfer of CPP32beta gene into malignant gliomas in vitro and in vivo. Cancer Res. 58:1998;962-967.
40. Ram Z., Culver K. W., Oshiro E. M., Viola J. J., DeVroom H. L., Otto E., Long Z., Chiang Y., McGarrity G. J., Muul L. M., Katz D., Blaese R. M., Oldfield E. H. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med. 3:1997;1354-1361.
41. Klatzmann D., Valery C. A., Bensimon G., Marro B., Boyer O., Mokhtari K., Diquet B., Salzmann J. L., Philippon J. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Hum. Gene Ther. 9:1998;2595-2604.
42. Long Z., Lu P., Grooms T., Mychkovsky I., Westley T., Fitzgerald T., Sharma-Chibber S., Shand N., McGarrity G., Otto E. Molecular evaluation of biopsy and autopsy specimens from patients receiving in vivo retroviral gene therapy. Hum. Gene Ther. 10:1999;733-740.
43. Puumalainen A. M., Vapalahti M., Agrawal R. S., Kossila M., Laukkanen J., Lehtolainen P., Viita H., Paljarvi L., Vanninen R., Yla-Herttuala S. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum. Gene Ther. 9:1998;1769-1774.
44. Eck S. L., Alavi J. B., Alavi A., Davis A., Hackney D., Judy K., Mollman J., Phillips P. C., Wheeldon E. B., Wilson J. M. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: A phase I trial. Hum. Gene Ther. 7:1996;1465-1482.
45. Shand N., Weber F., Mariani L., Bernstein M., Gianella-Borradori A., Long Z., Sorensen A. G., Barbier N. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum. Gene Ther. 10:1999;2325-2335.
46. Dewey R. A., Morrissey G., Cowsill C. M., Stone D., Bolognani F., Dodd N. J., Southgate T. D., Klatzmann D., Lassmann H., Castro M. G., Lowenstein P. R. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials. Nat. Med. 5:1999;1256-1263.
47. Morral N., O'Neal W., Rice K., Leland M., Kaplan J., Piedra P. A., Zhou H., Parks R. J., Velji R., Aguilar-Cordova E., Wadsworth S., Graham F. L., Kochanek S., Carey K. D., Beaudet A. L. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl. Acad. Sci. USA. 96:1999;12816-12821.
48. Shinoura N., Yoshida Y., Tsunoda R., Ohashi M., Zhang W., Asai A., Kirino T., Hamada H. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. Cancer Res. 59:1999;3411-3416.
49. Kokoris M., Sabo P., Adman E., Black M. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Ther. 6:1999;1415-1426.
50. Rainov N. G., Ikeda K., Qureshi N. H., Grover S., Herrlinger U., Pechan P., Chiocca E. A., Breakefield X. O., Barnett F. H. Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms. Hum. Gene Ther. 10:1999;311-318.
51. Kroll R. A., Pagel M. A., Muldoon L. L., Roman-Goldstein S., Fiamengo S. A., Neuwelt E. A. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: A comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers. Neurosurgery. 43:1998;879-889.
52. Blackburn R. V., Galoforo S. S., Corry P. M., Lee Y. J. Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity. Int. J. Cancer. 82:1999;293-297.
53. Kawashita Y., Ohtsuru A., Kaneda Y., Nagayama Y., Kawazoe Y., Eguchi S., Kuroda H., Fujioka H., Ito M., Kanematsu T., Yamashita S. Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation. Hum. Gene Ther. 10:1999;1509-1519.